1191 related articles for article (PubMed ID: 11907109)
1. Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin.
Seki N; Brooks AD; Carter CR; Back TC; Parsoneault EM; Smyth MJ; Wiltrout RH; Sayers TJ
J Immunol; 2002 Apr; 168(7):3484-92. PubMed ID: 11907109
[TBL] [Abstract][Full Text] [Related]
2. The Fas/Fas ligand pathway is important for optimal tumor regression in a mouse model of CTL adoptive immunotherapy of experimental CMS4 lung metastases.
Caldwell SA; Ryan MH; McDuffie E; Abrams SI
J Immunol; 2003 Sep; 171(5):2402-12. PubMed ID: 12928387
[TBL] [Abstract][Full Text] [Related]
3. T cell lysis of murine renal cancer: multiple signaling pathways for cell death via Fas.
Sayers TJ; Brooks AD; Seki N; Smyth MJ; Yagita H; Blazar BR; Malyguine AM
J Leukoc Biol; 2000 Jul; 68(1):81-6. PubMed ID: 10914493
[TBL] [Abstract][Full Text] [Related]
4. Anti-idiotype antibody induced cellular immunity in mice transgenic for human carcinoembryonic antigen.
Saha A; Chatterjee SK; Foon KA; Bhattacharya-Chatterjee M
Immunology; 2006 Aug; 118(4):483-96. PubMed ID: 16895556
[TBL] [Abstract][Full Text] [Related]
5. Molecular mechanisms of immune-mediated lysis of murine renal cancer: differential contributions of perforin-dependent versus Fas-mediated pathways in lysis by NK and T cells.
Sayers TJ; Brooks AD; Lee JK; Fenton RG; Komschlies KL; Wigginton JM; Winkler-Pickett R; Wiltrout RH
J Immunol; 1998 Oct; 161(8):3957-65. PubMed ID: 9780164
[TBL] [Abstract][Full Text] [Related]
6. Immunosensitization of melanoma tumor cells to non-MHC Fas-mediated killing by MART-1-specific CTL cultures.
Frost PJ; Butterfield LH; Dissette VB; Economou JS; Bonavida B
J Immunol; 2001 Mar; 166(5):3564-73. PubMed ID: 11207317
[TBL] [Abstract][Full Text] [Related]
7. Tumor regression after adoptive transfer of effector T cells is independent of perforin or Fas ligand (APO-1L/CD95L).
Winter H; Hu HM; Urba WJ; Fox BA
J Immunol; 1999 Oct; 163(8):4462-72. PubMed ID: 10510388
[TBL] [Abstract][Full Text] [Related]
8. In vivo rejection of tumor cells dependent on CD8 cells that kill independently of perforin and FasL.
Lee SH; Bar-Haim E; Machlenkin A; Goldberger O; Volovitz I; Vadai E; Tzehoval E; Eisenbach L
Cancer Gene Ther; 2004 Mar; 11(3):237-48. PubMed ID: 14739939
[TBL] [Abstract][Full Text] [Related]
9. Virally infected hepatocytes are resistant to perforin-dependent CTL effector mechanisms.
Kafrouni MI; Brown GR; Thiele DL
J Immunol; 2001 Aug; 167(3):1566-74. PubMed ID: 11466378
[TBL] [Abstract][Full Text] [Related]
10. Treatment of melanoma with 5-fluorouracil or dacarbazine in vitro sensitizes cells to antigen-specific CTL lysis through perforin/granzyme- and Fas-mediated pathways.
Yang S; Haluska FG
J Immunol; 2004 Apr; 172(7):4599-608. PubMed ID: 15034078
[TBL] [Abstract][Full Text] [Related]
11. Fas ligand (CD95L) protects neurons against perforin-mediated T lymphocyte cytotoxicity.
Medana I; Li Z; Flügel A; Tschopp J; Wekerle H; Neumann H
J Immunol; 2001 Jul; 167(2):674-81. PubMed ID: 11441070
[TBL] [Abstract][Full Text] [Related]
12. IFN-gamma promotes Fas ligand- and perforin-mediated liver cell destruction by cytotoxic CD8 T cells.
Roth E; Pircher H
J Immunol; 2004 Feb; 172(3):1588-94. PubMed ID: 14734739
[TBL] [Abstract][Full Text] [Related]
13. TNF plays an essential role in tumor regression after adoptive transfer of perforin/IFN-gamma double knockout effector T cells.
Poehlein CH; Hu HM; Yamada J; Assmann I; Alvord WG; Urba WJ; Fox BA
J Immunol; 2003 Feb; 170(4):2004-13. PubMed ID: 12574370
[TBL] [Abstract][Full Text] [Related]
14. Tc1 and Tc2 effector cell therapy elicit long-term tumor immunity by contrasting mechanisms that result in complementary endogenous type 1 antitumor responses.
Dobrzanski MJ; Reome JB; Hollenbaugh JA; Dutton RW
J Immunol; 2004 Feb; 172(3):1380-90. PubMed ID: 14734713
[TBL] [Abstract][Full Text] [Related]
15. Differential role of Fas/Fas ligand interactions in cytolysis of primary and metastatic colon carcinoma cell lines by human antigen-specific CD8+ CTL.
Bergmann-Leitner ES; Abrams SI
J Immunol; 2000 May; 164(9):4941-54. PubMed ID: 10779805
[TBL] [Abstract][Full Text] [Related]
16. ECH, an epoxycyclohexenone derivative that specifically inhibits Fas ligand-dependent apoptosis in CTL-mediated cytotoxicity.
Mitsui T; Miyake Y; Kakeya H; Osada H; Kataoka T
J Immunol; 2004 Mar; 172(6):3428-36. PubMed ID: 15004142
[TBL] [Abstract][Full Text] [Related]
17. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit T cell-mediated cytotoxicity by inhibiting Fas ligand expression.
Delgado M; Ganea D
J Immunol; 2000 Jul; 165(1):114-23. PubMed ID: 10861043
[TBL] [Abstract][Full Text] [Related]
18. Essential roles of perforin in antigen-specific cytotoxicity mediated by human CD4+ T lymphocytes: analysis using the combination of hereditary perforin-deficient effector cells and Fas-deficient target cells.
Yanai F; Ishii E; Kojima K; Hasegawa A; Azuma T; Hirose S; Suga N; Mitsudome A; Zaitsu M; Ishida Y; Shirakata Y; Sayama K; Hashimoto K; Yasukawa M
J Immunol; 2003 Feb; 170(4):2205-13. PubMed ID: 12574394
[TBL] [Abstract][Full Text] [Related]
19. Redirected perforin-dependent lysis of colon carcinoma by ex vivo genetically engineered CTL.
Darcy PK; Haynes NM; Snook MB; Trapani JA; Cerruti L; Jane SM; Smyth MJ
J Immunol; 2000 Apr; 164(7):3705-12. PubMed ID: 10725729
[TBL] [Abstract][Full Text] [Related]
20. NK cells use NKG2D to recognize a mouse renal cancer (Renca), yet require intercellular adhesion molecule-1 expression on the tumor cells for optimal perforin-dependent effector function.
Abdool K; Cretney E; Brooks AD; Kelly JM; Swann J; Shanker A; Bere EW; Yokoyama WM; Ortaldo JR; Smyth MJ; Sayers TJ
J Immunol; 2006 Aug; 177(4):2575-83. PubMed ID: 16888019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
